Timothy Myers

Mr. Timothy Myers

orcid
Sound Care in Every Breath

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2012 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Closed access
RDRajiv Dhand
Rajiv Dhand
MDMyrna Dolovich
Myrna Dolovich
BCBradley Chipps
Bradley Chipps
Timothy MyersTimothy Myers
Timothy Myers
RRRuben Restrepo
Ruben Restrepo
JFJudith Rosen Farrar
Judith Rosen Farrar
Current guidelines recommend inhalation therapy as the preferred route of drug administration for treating chronic obstructive pulmonary disease (COPD). Previous systematic reviews in COPD patients found similar clinical outcomes for drugs delivered by handheld inhalers - pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs) - and nebulizers, provided the devices were used correctly. However, in routine clinical practice critical errors in using handheld inhalers are highly prevalent and frequently result in inadequate symptom relief. In comparison with pMDIs and DPIs, effective drug delivery with conventional pneumatic nebulizers requires less intensive patient training. Moreover, by design, newer nebulizers are more portable and more efficient than traditional jet nebulizers. The current body of evidence regarding nebulizer use for maintenance therapy in patients with moderate-to-severe COPD, including use during exacerbations, suggests that the efficacy of long-term nebulizer therapy is similar, and in some respects superior, to that with pMDI/DPIs. Therefore, despite several known drawbacks associated with nebulized therapy, we recommend that maintenance therapy with nebulizers should be employed in elderly patients, those with severe disease and frequent exacerbations, and those with physical and/or cognitive limitations. Likewise, financial concerns and individual preferences that lead to better compliance may favor nebulized therapy over other inhalers. For some patients, using both nebulizers and pMDI/DPI may provide the best combination of efficacy and convenience. The impact of maintenance nebulizer treatment on other relevant clinical outcomes in patients with COPD, especially the progressive decline in lung function and frequency of exacerbations, needs further investigation.

1 December 2003 in The Journal of Pediatrics
Verified
Journal Article
Closed access
JCJohn C Carl
John C Carl
Timothy MyersTimothy Myers
Timothy Myers
HKH.LEster Kirchner
H.LEster Kirchner
CKCarolyn M Kercsmar
Carolyn M Kercsmar

1 January 2001 in The Journal of Pediatrics
Verified
Journal Article
Closed access
DCDaniel Craven
Daniel Craven
CKCarolyn M. Kercsmar
Carolyn M. Kercsmar
Timothy MyersTimothy Myers
Timothy Myers
MOMary Ann O’rIordan
Mary Ann O’rIordan
GGGregory Golonka
Gregory Golonka
SMScott Moore
Scott Moore

1 October 1998 in Archives of Pediatrics & Adolescent Medicine
Verified
Journal Article
Open access
PDF file
KMKaren M. McDowell
Karen M. McDowell
RCRobert L. Chatburn
Robert L. Chatburn
Timothy MyersTimothy Myers
Timothy Myers
MOMary Ann O'Riordan
Mary Ann O'Riordan
CKCarolyn M. Kercsmar
Carolyn M. Kercsmar
Objective To test the ability of an assessment-driven algorithm for treatment of pediatric status asthmaticus to reduce length and cost of hospitalization. Design Nonrandomized, prospective, controlled trial. Setting Tertiary care children's hospital. Patients Children aged 1 to 18 years hospitalized for status asthmaticus; 104 were treated using the asthma care algorithm (intervention) and 97 using unstructured standard treatment (control). Intervention Patients were treated using either an assessment-based algorithm or standard care practices. The algorithm group was treated with standard medications (aerosolized albuterol, systemic corticosteroids, epinephrine, ipratropium) administered at a frequency driven by the patient's clinical condition. Specific criteria were outlined for decreasing or augmenting therapy, transferring to intensive care, and discharging to home. A unique patient record containing assessments, algorithm cues, and a treatment record was used. Intervention group patients were interviewed by telephone 1 week after discharge. Main Outcome Measures Hospital length of stay, cost per hospitalization, relapse rate, protocol adherence. Results Average hospital stay for intervention patients was significantly shorter than for control patients (2.0 vs 2.9 days,P<.001). Although intervention patients received fewer aerosolized albuterol doses than controls, there was no difference in short-term relapse rate between groups. The intervention saved more than $700 per patient in hospital charges. Adherence to the protocol was excellent, with only 8 variances per patient stay out of more than 150 opportunities. Conclusion An intensive, assessment-driven algorithm for pediatric status asthmaticus significantly reduces hospital length of stay and costs without increasing morbidity.

1 September 2011 in Respiratory Care
Verified
Journal Article
Open access
PDF file
Timothy MyersTimothy Myers
Timothy Myers
LTLiza Tomasio
Liza Tomasio
Asthma is a multifactorial, chronic inflammatory disease of the airways. The knowledge that asthma is an inflammatory disorder has become a core fundamental in the definition of asthma. Asthma's chief features include a variable degree of air-flow obstruction and bronchial hyper-responsiveness, in addition to the underlying chronic airways inflammation. This underlying chronic airway inflammation substantially contributes to airway hyper-responsiveness, air-flow limitation, respiratory symptoms, and disease chronicity. However, this underlying chronic airway inflammation has implications for the diagnosis, management, and potential prevention of the disease. This review for the respiratory therapy community summarizes these developments as well as providing an update on asthma epidemiology, natural history, cause, and pathogenesis. This paper also provides an overview on appropriate diagnostic and monitoring strategies for asthma, pharmacology, and newer therapies for the future as well as relevant management of acute and ambulatory asthma, and a brief review of educational approaches.

1 March 2000
Verified
Journal Article
Closed access
Timothy MyersTimothy Myers
Timothy Myers
Despite significant advances in understanding the pathophysiology of asthma and the development of pharmacologic agents for treatment, asthma prevalence, morbidity, and mortality continue to increase in most countries. This Article focuses on the epidemiology of asthma, specifically on the prevalence, incidence, morbidity, and mortality associated with pediatric asthma.